🇺🇸 Piroxicam-Beta-Cyclodextrin in United States
4 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 4
Most-reported reactions
- Asthma — 1 report (25%)
- Drug Effect Decreased — 1 report (25%)
- Fluid Overload — 1 report (25%)
- Sarcoidosis — 1 report (25%)
Other Rheumatology / Pain Management approved in United States
Frequently asked questions
Is Piroxicam-Beta-Cyclodextrin approved in United States?
Piroxicam-Beta-Cyclodextrin does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Piroxicam-Beta-Cyclodextrin in United States?
Universidade Federal de Sergipe is the originator. The local marketing authorisation holder may differ — check the official source linked above.